Generic name |
bosentan |
---|---|
Strength |
62.5 mg, 125 mg |
Form |
tablet |
Special Authority criteria |
Approval period |
---|---|
As monotherapy, for the treatment of World Health Organization (WHO)/New York Heart Association (NYHA) functional class III or IV pulmonary arterial hypertension (PAH). The usual dose of bosentan should be limited to a maximum of 125mg twice daily. |
1 year |